Executive Summary
This period's $4.99B in contract option exercises signals strong federal commitment to healthcare (VA/HHS ~$2.8B or 56%), IT services (~$1.1B or 22%), and defense/space systems, with 12/15 bullish awards dominated by full/open competition wins. Largest awards (> $400M) to TriWest, L3Harris, BL Harbert highlight revenue visibility through 2026-2032, though short-duration outliers like TriWest's $820M 1-month deal raise execution questions. Investors should prioritize VA/IT exposed large caps (L3Harris, Lockheed) and monitor option exercises for ~$2B+ upside across contracts.
Tracking the trend? Catch up on the prior Contract Option Exercises digest from March 12, 2026.
Investment Signals(3)
- VA Healthcare Surge(HIGH)▲
Five VA awards totaling $1.65B (33% of period value) to TriWest, Veterans Evaluation, Cognosante, Technatomy, Richard Group via full/open competition signal robust demand for medical/IT services.
- HHS Biotech/IT Momentum(HIGH)▲
Four HHS awards worth $1.1B to Advanced Tech Int, MAPP Bio, ThirdPacket for R&D/IT underscore BARDA/CMS funding stability through 2029+.
- Defense Prime Stability(MEDIUM)▲
L3Harris ($814M NASA to 2029), Lockheed ($65M DHS to 2026), Boeing sub Insitu ($96M DHS to 2026) provide long-term revenue in space/C4ISR.
Risk Flags(3)
- Execution[HIGH RISK]▼
Firm fixed price prevalent (9/15 contracts) exposes winners like TriWest, BL Harbert to cost overruns; long periods (avg ~5yrs) in 11/15 amplify delays/obsolescence.
- Market[MEDIUM RISK]▼
Low/zero outlays in 8/15 ($2.1B value) including TriWest ($820M, $0 outlaid), BL Harbert ($814M, $0) signal delayed cash flows amid future starts (e.g., 2026).
- Competitive[MEDIUM RISK]▼
Heavy subawards (e.g., L3Harris $169M/538 subs, Salient $187M/128) create subcontractor dependencies; non-competed awards (3/15) like BL Harbert limit rivalry but risk sole-source scrutiny.
Opportunities(3)
- ◆
$2B+ in unobligated options (e.g., Salient $454M, MAPP $722M, Cognosante $241M) offer expansion if exercised.
- ◆
Set-aside advantages for vet/SDVOSB/8(a) winners (Technatomy, Richard Group, ThirdPacket, ITSI; $352M total) position for repeat VA/HHS/DHS work.
- ◆
Short-duration high-value like TriWest $820M (1-mo Feb 2026) could seed follow-on VA insurance deals post-execution.
Sector Themes(2)
- ◆
VA/HHS dominate with $2.8B (56%) across medical eval, DevSecOps, biotech R&D; full competition wins to non-profits/small biz signal sustained outlays.
- ◆
Aerospace/engineering awards (L3Harris, Lockheed, Insitu) total $973M through 2029+ with cost-plus flexibility.
Watch List(4)
- 👁
{"entity"=>"TriWest Healthcare", "reason"=>"$820M VA award is largest/single-month outlier; $0 outlay/execution post-Feb 2026 critical for follow-ons.", "trigger"=>"outlays >10% by Q2 2026 or missed performance"}
- 👁
{"entity"=>"L3Harris Technologies", "reason"=>"$814M NASA to 2029 with $216M outlaid anchors space revenue; $19M options upside.", "trigger"=>"subaward delays or tech milestone slips"}
- 👁
{"entity"=>"MAPP Biopharmaceutical", "reason"=>"Small biz with $185M obligated/$906M ceiling in viral therapeutics; BARDA options key to scaling.", "trigger"=>"option exercise announcements"}
- 👁
{"entity"=>"VA IT Contractors (Cognosante, Technatomy)", "reason"=>"$377M combined with $234M outlaid/options; DevSecOps trend for multi-year growth.", "trigger"=>"extension to potential ends (2026-2029)"}
Get daily alerts with 3 investment signals, 3 risk alerts, 3 opportunities and full AI analysis of all 15 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC